Research
Novel Epinephrine Devices Promising in Mid-Stage Trials
The Brief
- Novel epinephrine formulations are advancing through mid-stage trials.
- Promising data on these devices were presented at the American College of Allergy, Asthma & Immunology (ACAAI) annual meeting.
- Source coverage is a brief summary; the full trial details are not available in the provided text.
Why it matters
Epinephrine is the standard treatment for severe allergic reactions, so improvements in how it is delivered could matter to patients and clinicians who rely on it.
Who’s affected
- allergists and immunologists
- patients with severe allergies and their families
(MedPage Today) -- Novel epinephrine formulations are advancing through mid-stage trials, with promising data presented at the American College of Allergy, Asthma & Immunology (ACAAI) annual meeting. "For years, patients' families' voice has...